retatrutide dosing trials Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial Triple hormone receptor agonist retatrutide

Rights and permissions Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made

"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) - Lilly Clinical Trials"

Check our guide on how to give a SubQ injection Your clinician will consider your schedule, tolerance during and after administration, and your program goals when recommending route and frequency

As well as nausea and diarrhea, these can extend to more complex or longer-term problems, like gastroesophageal reflux disease, gastroparesis (paralysis of the stomach), and inflammation of the colon

This influences the neuroendocrine regulation of hunger and satiety, leading to reduced food intake without conscious effort to limit calories

10.1172/JCI117480 J Clin Invest